Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings
IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
Authors
- Ana E. Limon
- Khursheed Anwer
- William H. Bradley (ORCID: https://orcid.org/0000-0002-6949-5262)
- Stacy R. Lindborg (ORCID: https://orcid.org/0000-0002-0103-2552)
- Premal H Thaker
- Douglas V Faller
- Ronald D Alvarez
Institutions
- Medical College of Wisconsin (US)
- Immersion (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/13543784.2026.2636926
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00